ID   A431/GPC3+
AC   CVCL_F6LD
SY   G1; A431-GPC3
RX   PubMed=25758784;
CC   Population: Caucasian.
CC   Characteristics: Stably expresses human GPC3.
CC   Sequence variation: Gene fusion; HGNC; HGNC:3236; EGFR + HGNC; HGNC:9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:4451; GPC3.
CC   Derived from site: In situ; Skin, epidermis; UBERON=UBERON_0001003.
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0037 ! A-431
SX   Female
AG   85Y
CA   Cancer cell line
DT   Created: 22-10-26; Last updated: 22-10-26; Version: 1
CH   CVCL_F6LE ! A431/Luc GPC3+
//
RX   PubMed=25758784; DOI=10.1038/ncomms7536; PMCID=PMC4357278;
RA   Gao, Wei
RA   Tang, Zhewei
RA   Zhang, Yi-Fan
RA   Feng, Mingqian
RA   Qian, Min
RA   Dimitrov, Dimiter S.
RA   Ho, Mitchell
RT   "Immunotoxin targeting glypican-3 regresses liver cancer via dual
RT   inhibition of Wnt signalling and protein synthesis.";
RL   Nat. Commun. 6:6536-6536(2015).
//